Harness Therapeutics
- Biotech or pharma, therapeutic R&D
Unlocking New Targets to Transform Treatment of Neurodegenerative Diseases
Harness Therapeutics is a UK-based RNA platform company focussed on controlled upregulation of CNS targets. Our platform for post-transcriptional upregulation uses proprietary miRNA site-blocking constructs to drive controlled increases in target protein level and so allow targets involved in complex biology to be addressed.
Our lead programme targets FAN1 nuclease, the somatic-expansion target with the strongest link to disease onset in Huntington's disease and other triplet disorders
We have additional programmes focussed on first-in-class targets for ALS, AD, PD.
Harness is seed funded by Takeda Ventures, DDF(SV Health), Epidarex Capital and Ono Ventures. We are targeting a clinical-data delivering Series A during 2025, following selection of a HD Development Candidate.
We are seeking partnerships to drive portfolio acceleration/commercialisation and expansion to further CNS upregulation targets.
Address
CambridgeCambridgeshire
United Kingdom
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}